GSK vs. HLN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at GSK and HLN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Both GSK and HLN are American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies.
| Symbol | GSK | HLN |
|---|---|---|
| Company Name | GSK plc | Haleon plc |
| Country | United Kingdom | United Kingdom |
| GICS Sector | Health Care | Consumer Staples |
| GICS Industry | Pharmaceuticals | Personal Care Products |
| Market Capitalization | 80.40 billion USD | 43.52 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | March 28, 1980 | July 25, 2022 |
| Security Type | ADR | ADR |
Historical Performance
This chart compares the performance of GSK and HLN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | GSK | HLN |
|---|---|---|
| 5-Day Price Return | 1.24% | -0.80% |
| 13-Week Price Return | 1.48% | -13.43% |
| 26-Week Price Return | 2.23% | -8.37% |
| 52-Week Price Return | -11.02% | -4.46% |
| Month-to-Date Return | 3.63% | -0.47% |
| Year-to-Date Return | 9.13% | -5.19% |
| 10-Day Avg. Volume | 4.90M | 12.30M |
| 3-Month Avg. Volume | 6.79M | 16.72M |
| 3-Month Volatility | 24.77% | 16.51% |
| Beta | 0.96 | 0.40 |
Profitability
Return on Equity (TTM)
GSK
24.18%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
In the upper quartile for the Pharmaceuticals industry, GSK’s Return on Equity of 24.18% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
HLN
3.26%
Personal Care Products Industry
- Max
- 31.59%
- Q3
- 20.42%
- Median
- 11.01%
- Q1
- 3.26%
- Min
- -18.42%
HLN’s Return on Equity of 3.26% is on par with the norm for the Personal Care Products industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
GSK
10.82%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
GSK’s Net Profit Margin of 10.82% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
HLN
12.84%
Personal Care Products Industry
- Max
- 15.12%
- Q3
- 12.06%
- Median
- 9.26%
- Q1
- 5.50%
- Min
- -0.40%
A Net Profit Margin of 12.84% places HLN in the upper quartile for the Personal Care Products industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
GSK
16.22%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
GSK’s Operating Profit Margin of 16.22% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
HLN
19.64%
Personal Care Products Industry
- Max
- 19.80%
- Q3
- 17.96%
- Median
- 13.14%
- Q1
- 7.58%
- Min
- -4.25%
An Operating Profit Margin of 19.64% places HLN in the upper quartile for the Personal Care Products industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | GSK | HLN |
|---|---|---|
| Return on Equity (TTM) | 24.18% | 3.26% |
| Return on Assets (TTM) | 5.77% | 1.58% |
| Net Profit Margin (TTM) | 10.82% | 12.84% |
| Operating Profit Margin (TTM) | 16.22% | 19.64% |
| Gross Profit Margin (TTM) | 71.77% | 60.75% |
Financial Strength
Current Ratio (MRQ)
GSK
0.87
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
GSK’s Current Ratio of 0.87 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
HLN
0.87
Personal Care Products Industry
- Max
- 4.26
- Q3
- 2.61
- Median
- 1.74
- Q1
- 1.13
- Min
- 0.76
HLN’s Current Ratio of 0.87 falls into the lower quartile for the Personal Care Products industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
GSK
1.17
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
GSK’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.17. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
HLN
0.53
Personal Care Products Industry
- Max
- 1.13
- Q3
- 0.63
- Median
- 0.26
- Q1
- 0.04
- Min
- 0.00
HLN’s Debt-to-Equity Ratio of 0.53 is typical for the Personal Care Products industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
GSK
2.37
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
In the lower quartile for the Pharmaceuticals industry, GSK’s Interest Coverage Ratio of 2.37 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
HLN
8.00
Personal Care Products Industry
- Max
- 96.53
- Q3
- 59.91
- Median
- 22.25
- Q1
- 7.85
- Min
- -1.93
HLN’s Interest Coverage Ratio of 8.00 is positioned comfortably within the norm for the Personal Care Products industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | GSK | HLN |
|---|---|---|
| Current Ratio (MRQ) | 0.87 | 0.87 |
| Quick Ratio (MRQ) | 0.57 | 0.63 |
| Debt-to-Equity Ratio (MRQ) | 1.17 | 0.53 |
| Interest Coverage Ratio (TTM) | 2.37 | 8.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
GSK
4.26%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.26%, GSK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
HLN
0.72%
Personal Care Products Industry
- Max
- 4.08%
- Q3
- 2.46%
- Median
- 1.82%
- Q1
- 0.83%
- Min
- 0.00%
HLN’s Dividend Yield of 0.72% is in the lower quartile for the Personal Care Products industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio (TTM)
GSK
54.01%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
GSK’s Dividend Payout Ratio of 54.01% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
HLN
954.40%
Personal Care Products Industry
- Max
- 207.61%
- Q3
- 115.17%
- Median
- 69.37%
- Q1
- 47.71%
- Min
- 0.00%
At 954.40%, HLN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Personal Care Products industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | GSK | HLN |
|---|---|---|
| Dividend Yield (TTM) | 4.26% | 0.72% |
| Dividend Payout Ratio (TTM) | 54.01% | 954.40% |
Valuation
Price-to-Earnings Ratio (TTM)
GSK
17.09
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
GSK’s P/E Ratio of 17.09 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
HLN
22.43
Personal Care Products Industry
- Max
- 55.49
- Q3
- 36.75
- Median
- 26.49
- Q1
- 22.40
- Min
- 11.12
HLN’s P/E Ratio of 22.43 is within the middle range for the Personal Care Products industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
GSK
1.85
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
GSK’s P/S Ratio of 1.85 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
HLN
2.88
Personal Care Products Industry
- Max
- 5.35
- Q3
- 2.83
- Median
- 2.07
- Q1
- 1.13
- Min
- 0.00
HLN’s P/S Ratio of 2.88 is in the upper echelon for the Personal Care Products industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
GSK
3.84
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
GSK’s P/B Ratio of 3.84 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
HLN
2.11
Personal Care Products Industry
- Max
- 7.32
- Q3
- 5.26
- Median
- 2.93
- Q1
- 1.84
- Min
- 1.14
HLN’s P/B Ratio of 2.11 is within the conventional range for the Personal Care Products industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | GSK | HLN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 17.09 | 22.43 |
| Price-to-Sales Ratio (TTM) | 1.85 | 2.88 |
| Price-to-Book Ratio (MRQ) | 3.84 | 2.11 |
| Price-to-Free Cash Flow Ratio (TTM) | 12.54 | 15.04 |